Therapeutic Area | MeSH |
---|---|
cardiovascular diseases | D002318 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
TEKTURNA | Noden Pharma | N-021985 RX | 2007-03-05 | 2 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
TEKTURNA HCT | Noden Pharma | N-022107 DISCN | 2008-01-18 | 4 products, RLD |
Brand Name | Status | Last Update |
---|---|---|
aliskiren | NDA authorized generic | 2023-05-25 |
tekturna | New Drug Application | 2024-02-13 |
tekturna hct | New Drug Application | 2022-11-16 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
hypertension | EFO_0000537 | D006973 | I10 |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Aliskiren Hemifumarate / Amlodipine Besylate, Tekamlo, Novartis | |||
8613949 | 2029-12-21 | DP | |
Aliskiren Hemifumarate / Hydrochlorothiazide, Tekturna Hct, Noden Pharma | |||
8618172 | 2028-07-13 | DP | |
Aliskiren Hemifumarate / Valsartan, Valturna, Novartis | |||
8168616 | 2026-07-03 | DP | |
Aliskiren Hemifumarate, Tekturna, Noden Pharma | |||
8617595 | 2026-02-19 | DP | |
Aliskiren Hemifumarate / Amlodipine Besylate / Hydrochlorothiazide, Amturnide, Novartis | |||
8183295 | 2023-05-16 | DP |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hypertension | D006973 | EFO_0000537 | I10 | 6 | 9 | 38 | 37 | 5 | 94 |
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 3 | 3 | 1 | 6 | 1 | 11 |
Heart failure | D006333 | HP_0001635 | I50 | — | 3 | 3 | 3 | 1 | 10 |
Essential hypertension | D000075222 | — | I10 | — | — | 5 | 3 | — | 8 |
Chronic renal insufficiency | D051436 | — | N18 | — | — | — | 5 | — | 5 |
Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | 2 | 1 | — | 2 | — | 5 |
Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | 1 | — | — | 3 | 1 | 5 |
Proteinuria | D011507 | HP_0000093 | R80 | — | — | — | 4 | — | 4 |
Iga glomerulonephritis | D005922 | EFO_0004194 | — | — | — | 1 | 3 | — | 4 |
Left ventricular hypertrophy | D017379 | EFO_0003896 | — | — | — | 1 | 2 | — | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | 1 | 1 | — | 1 | 2 |
Overweight | D050177 | — | E66.3 | — | — | 1 | — | — | 1 |
Marfan syndrome | D008382 | Orphanet_558 | Q87.4 | — | — | 1 | — | — | 1 |
Cardiovascular diseases | D002318 | HP_0001626 | — | — | — | 1 | — | — | 1 |
Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | 1 | — | — | 1 |
Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Insulin resistance | D007333 | HP_0000855 | E88.819 | — | 1 | — | — | 1 | 2 |
Acute coronary syndrome | D054058 | EFO_0005672 | — | — | 1 | — | — | — | 1 |
Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | 1 | — | — | — | 1 |
Macular edema | D008269 | — | — | — | 1 | — | — | — | 1 |
Glomerulonephritis | D005921 | HP_0000099 | N05 | — | 1 | — | — | — | 1 |
Membranoproliferative glomerulonephritis | D015432 | — | — | — | 1 | — | — | — | 1 |
Renal insufficiency | D051437 | HP_0000083 | N19 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
Glucose metabolism disorders | D044882 | — | — | 1 | — | — | — | — | 1 |
Metabolic diseases | D008659 | EFO_0000589 | E88.9 | 1 | — | — | — | — | 1 |
Endocrine system diseases | D004700 | EFO_0001379 | E34.9 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Covid-19 | D000086382 | — | U07.1 | — | — | — | — | 1 | 1 |
Abdominal aortic aneurysm | D017544 | EFO_0004214 | — | — | — | — | — | 1 | 1 |
Diastolic heart failure | D054144 | EFO_1000899 | I50.30 | — | — | — | — | 1 | 1 |
Drug common name | Aliskiren |
INN | aliskiren |
Description | Aliskiren is a monomethoxybenzene compound having a 3-methoxypropoxy group at the 2-position and a multi-substituted branched alkyl substituent at the 4-position. It has a role as an antihypertensive agent. It is a monomethoxybenzene and a monocarboxylic acid amide. |
Classification | Small molecule |
Drug class | renin inhibitors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC |
PDB | — |
CAS-ID | 173334-57-1 |
RxCUI | — |
ChEMBL ID | CHEMBL1639 |
ChEBI ID | 601027 |
PubChem CID | 5493444 |
DrugBank | DB01258 |
UNII ID | 502FWN4Q32 (ChemIDplus, GSRS) |